The RAGE signaling in osteoporosis

Osteoporosis (OP), characterized by an imbalance of bone remodeling between formation and resorption, has become a health issue worldwide. The receptor for advanced glycation end product (RAGE), a transmembrane protein in the immunoglobin family, has multiple ligands and has been involved in many chronic diseases, such as diabetes and OP. Increasing evidence shows that activation of the RAGE signaling negatively affects bone remodeling. Ligands, such as advanced glycation end products (AGEs), S100, beta-amyloid (A beta), and high mobility group box 1 (HMGB1), have been well documented that they may negatively regulate the proliferation and differentiation of osteoblasts and positively stimulate osteoclastogenesis by activating the expression of RAGE. In this review, we comprehensively discuss the structure of RAGE and its biological functions in the pathogenesis of OP. The research findings suggest that RAGE signaling has become a potential target for the therapeutic management of OP.

Automated summary

Osteoporosis is a worldwide health issue characterized by imbalanced bone remodeling. The receptor for advanced glycation end product (RAGE), a transmembrane protein in the immunoglobin family, has been involved in many chronic diseases, including osteoporosis. Activation of RAGE signaling negatively affects bone remodeling by regulating osteoblast proliferation and differentiation, as well as osteoclastogenesis. The review discusses the structure of RAGE and its biological functions in the pathogenesis of osteoporosis, suggesting RAGE signaling as a potential therapeutic target.